Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Glen Allen, Virginia.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [06/30/2025 07:09 PDT] ADIL Expected to Trade Up After Bullish Patterns Develop
• [06/17/2025 10:29 PDT] Adial Pharmaceuticals, Inc. (NASDAQ:ADIL), Down By 100% ($0.36) From $0.358 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [06/16/2025 07:10 PDT] ADIL Expected to Trade Down After Bearish Patterns Develop
• [05/08/2025 07:12 PDT] ADIL Expected to Trade Up After Bullish Patterns Develop
• [05/07/2025 06:54 PDT] ADIL Expected to Trade Up After Bullish Patterns Develop